Tributyrin
- Generic Name
- Tributyrin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C15H26O6
- CAS Number
- 60-01-5
- Unique Ingredient Identifier
- S05LZ624MF
- Background
Tributyrin has been used in trials studying the treatment of Prostate Cancer and Unspecified Adult Solid Tumor, Protocol Specific.
- Associated Conditions
- -
- Associated Therapies
- -
Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Tributyrin Supplementation
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Nicolaas Bohnen, MD, PhD
- Target Recruit Count
- 18
- Registration Number
- NCT05446168
- Locations
- 🇺🇸
University of Michigan Health System Functional Neuroimaging, Cognitive and Mobility Laboratory, Ann Arbor, Michigan, United States
Tributyrin in Treating Patients With Refractory Prostate Cancer or Other Solid Tumors
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-05-11
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 24
- Registration Number
- NCT00002677
- Locations
- 🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath